Brief: Chemocentryx And Vfmcrp Provide Topline Results From Accolade Trial Of Avacopan In C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate
21/12/2020 23:20
Dec 21 (Reuters) - ChemoCentryx Inc CCXI.O :
* CHEMOCENTRYX AND VFMCRP PROVIDE TOPLINE RESULTS FROM
ACCOLADE
TRIAL OF AVACOPAN IN C3 GLOMERULOPATHY INCLUDING IMPROVED
ESTIMATED GLOMERULAR FILTRATION RATE (EGFR)
* CHEMOCENTRYX INC - AVACOPAN WAS SAFE AND WELL TOLERATED IN
TRIAL
Source text for Eikon: ID:nGNX9LpnvF
Further company coverage: CCXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Churchill Capital XI
See all newsBrief: AGCO To Pilot Digit Humanoid Robot At Hesston, Kansas Facility In 2027
Brief: Agility Robotics Announces Audit Committee Chair For Planned Public-Company Board
Brief: Agility Robotics And Churchill Capital Corp Xi S-4 Registration Statement Declared Effective By SEC In Connection With Proposed Business Combination
Brief: Agility And Fort Robotics Announce Strategic Partnership To Advance Humanoid Robot Safety
Deals of the day-Mergers and acquisitions